Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan 20:9:2.
doi: 10.1186/1471-2318-9-2.

Quantifying the profile and progression of impairments, activity, participation, and quality of life in people with Parkinson disease: protocol for a prospective cohort study

Meg E Morris  1 , Jennifer J Watts, Robert Iansek, Damien Jolley, Donald Campbell, Anna T Murphy, Clarissa L Martin
Affiliations

Quantifying the profile and progression of impairments, activity, participation, and quality of life in people with Parkinson disease: protocol for a prospective cohort study

Meg E Morris et al. BMC Geriatr. .

Abstract

Background: Despite the finding that Parkinson disease (PD) occurs in more than one in every 1000 people older than 60 years, there have been few attempts to quantify how deficits in impairments, activity, participation, and quality of life progress in this debilitating condition. It is unclear which tools are most appropriate for measuring change over time in PD.

Methods and design: This protocol describes a prospective analysis of changes in impairments, activity, participation, and quality of life over a 12 month period together with an economic analysis of costs associated with PD. One-hundred participants will be included, provided they have idiopathic PD rated I-IV on the modified Hoehn & Yahr (1967) scale and fulfil the inclusion criteria. The study aims to determine which clinical and economic measures best quantify the natural history and progression of PD in a sample of people receiving services from the Victorian Comprehensive Parkinson's Program, Australia. When the data become available, the results will be expressed as baseline scores and changes over 3 months and 12 months for impairment, activity, participation, and quality of life together with a cost analysis.

Discussion: This study has the potential to identify baseline characteristics of PD for different Hoehn & Yahr stages, to determine the influence of disease duration on performance, and to calculate the costs associated with idiopathic PD. Valid clinical and economic measures for quantifying the natural history and progression of PD will also be identified.

Trial registration: ACTRN12609000008224.

PubMed Disclaimer

References

    1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–386. doi: 10.1212/01.wnl.0000247740.47667.03. - DOI - PubMed
    1. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: The Rotterdam Study. Neurology. 2004;63:1240–1244. - PubMed
    1. Australian Institute of Health and Welfare http://www.aihw.gov.au/publications/aus/ah06/ah06-c03.pdf
    1. Lindgren P, von Campenhausen S, Spottke E, Siebert U, Dodel R. Cost of Parkinson's disease in Europe. European Journal of Neurology. 2005;12:68–73. doi: 10.1111/j.1468-1331.2005.01197.x. - DOI - PubMed
    1. Cordato DJ, Schwartz R, Abbott E, Saunders R, Morfis L. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia. Journal of Clinical Neuroscience. 2006;13:655–658. doi: 10.1016/j.jocn.2005.09.006. - DOI - PubMed

Publication types